Quantum Cyber N.V. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2026; filed November 12, 2026. The company, formerly Mainz Biomed N.V., pivoted from cancer diagnostics toward autonomous defense, drones and quantum technologies. It acquired Arcade Metal Stamping and its Bridgeport, Connecticut facility in July; that business generated all continuing-operations revenue reported this period.
Key financial metrics
| Metric | Three months ended Sept. 30, 2026 | Nine months ended Sept. 30, 2026 |
|---|---|---|
| Continuing revenue | $966,833 | $966,833 |
| Gross profit / margin | $93,590 / 9.7% | $93,590 / 9.7% |
| Operating expenses | $4,955,601 | $17,506,705 |
| Continuing-operations loss | $4,920,169 | $17,478,084 |
| Net loss, including discontinued operations | $5,381,441 | $21,479,903 |
| Operating cash flow, continuing operations | Not provided for the quarter | $(9,731,639) |
For comparison, the nine-month 2025 net loss was $11.4 million and continuing-operations revenue was nil. The nine-month 2026 loss per ordinary share was $0.69, versus $2.30 in 2025; the weighted-average share count rose to 31.3 million from 4.9 million, materially affecting per-share comparisons.
- Cash and liquidity: September 30 cash was $4.86 million in continuing operations and $4.89 million including discontinued operations. Working capital was approximately $6.3 million. Nine-month continuing operating and investing cash outflows were $9.7 million and $4.9 million, respectively.
- Balance sheet and debt: Total assets were $18.8 million, total liabilities $2.6 million, and shareholders’ equity $16.2 million. The filing reports no material long-term borrowing; liabilities include a $750,000 Project LightShift license liability and operating lease obligations of about $351,000.
- Funding: Financing provided $18.8 million of continuing-operations cash in the first nine months, including $15.2 million from warrant exercises, $6.0 million from preferred-share sales and $2.1 million from ordinary-share sales, offset by repayments and other items.
Material changes and notable items
- Arcade contributed $966,833 in revenue after its July 15 acquisition. Revenue was metal stamping and electrical products; the company had not begun drone sales and reported no drone purchase orders.
- Operating expenses increased substantially year over year, reflecting the new business, staffing and facility build-out. Nine-month R&D included $4.26 million of acquired in-process R&D for the Project LightShift quantum-antenna license, expensed because the technology was in development and limited to one field of use. The BP United drone-technology license was capitalized at $5.47 million, substantially as share consideration.
- Discontinued colorectal-cancer operations recorded a $4.00 million nine-month loss, down from $5.74 million in 2025. The company expects related held-for-sale assets and liabilities to be settled in the first quarter of 2027.
- Share issuance and potential dilution are significant. At September 30, 87.2 million ordinary shares were outstanding; remaining Series D and E preferred shares were convertible into approximately 421.9 million ordinary shares in total. The filing also reports substantial share-based payments and shares issued or issuable under license and advisory arrangements.
Outlook, risks and contingencies
- Management expects to begin manufacturing and selling drones in early 2027, but says facility delays have pushed back its timeline and gives no assurance of launch or market acceptance. The Bridgeport build-out, equipment procurement and prototype development were ongoing.
- The company reported recurring losses and negative operating cash flows that raised substantial doubt about its ability to continue as a going concern. Management says the doubt is alleviated for at least one year after issuance based on cash and a November 11 commitment from CEO and Chair David Lazar to provide up to $8.0 million through November 30, 2027, as needed. Funding terms remain to be agreed; no amount had been funded by issuance.
- An October 9 at-the-market agreement permits sales of up to $100 million of ordinary shares, with a 3% agent commission. No shares had been sold through November 12. The company warns that financing may not be available and that equity funding could dilute shareholders.
- The company disclosed ineffective disclosure controls and a material weakness in financial reporting, involving control documentation, review precision, system access and segregation of duties. Material weaknesses were also identified at the acquired Arcade business; remediation and integration remain in progress.
- Other key risks include manufacturing and technology-development delays, no drone orders, reliance on third-party licenses and a Project LightShift prototype milestone, regulatory and procurement requirements, customer and supplier concentration, competition, cyber and AI-performance risks, and continued Nasdaq listing compliance.
- Subsequent events include a $250,000 Boustead legal settlement, paid October 16 and accrued at September 30, and a November amendment expanding Project LightShift’s licensed applications. No material litigation amount beyond the disclosed settlement is clearly quantified.
Important facts for investors to verify
- Whether the Lazar funding commitment is documented on workable terms and whether any funds are drawn; distinguish this commitment from cash already on hand.
- Progress, costs and schedule for Bridgeport facility completion, drone manufacturing, prototypes, required approvals and customer orders.
- Arcade’s recurring revenue, customer concentration, margins and cash conversion; the reported period includes only post-acquisition results.
- The potential dilution and governance implications of Series D/E conversion rights, the ATM, and shares promised or issued for licenses and services.
- Remediation of the company’s and Arcade’s material weaknesses, and the effect of the disclosed Form S-3 eligibility issue on future fundraising.